SCHEMBL17758802

SCHEMBL17758802

COC(c1cccc(-n2cccn2)c1)c1cnc(Cl)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
RAB9A P51151 1/20 0.39
NOTUM Q6P988 1/20 0.36
IDH1 O75874 1/20 0.35
NPBWR1 P48145 1/20 0.34
MCHR1 Q99705 1/20 0.34
MET P08581 1/20 0.33
HCRTR1 O43613 2/20 0.33
HCRTR2 O43614 2/20 0.33
PI4KB Q9UBF8 1/20 0.33
RXRA P19793 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2B Q13224 1/20 0.33
MAPT P10636 2/20 0.33
SYK P43405 1/20 0.32
BACE1 P56817 1/20 0.32
BACE2 Q9Y5Z0 1/20 0.32
KDM5B Q9UGL1 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17758865 0.85 IDH1 (0.38) LMNANOTUMIDH1NPBWR1MCHR1
SCHEMBL17758752 0.84 NOTUM (0.39) LMNANOTUMIDH1PI4KBGRIN1
SCHEMBL20929258 0.73 POLB (0.36) LMNANOTUMMETMAPTKDM4E
SCHEMBL21695587 0.73 LMNA (0.36) LMNARAB9AHCRTR1HCRTR2MAPT
SCHEMBL17758753 0.72 NOTUM (0.49) NOTUMKDM4EALDH1A1MAPK1
SCHEMBL23352228 0.72 NOTUM (0.36) LMNANOTUMMETMAPTKDM4E
SCHEMBL21695609 0.72 PDGFRB (0.35) LMNARAB9AGRIN1GRIN2BMAPT
SCHEMBL21695586 0.71 MLYCD (0.34) LMNARAB9AMAPTSYKALDH1A1
SCHEMBL23352192 0.70 USP9X (0.41) NPBWR1HCRTR1HCRTR2MAPTKDM4E
SCHEMBL23352236 0.70 USP9X (0.45) LMNANPBWR1MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11358961-B2 Anti-HCMV compositions and methods EVRYS BIO, LLC (US) 2022-06-14 US disclosed
US-20220135556-A1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO, LLC (US) 2022-05-05 US disclosed
EP-3218373-B1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO LLC (US) 2020-07-22 EP disclosed
US-20200140429-A1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO, LLC (US) 2020-05-07 US disclosed
US-10556894-B2 Anti-HCMV compositions and methods EVRYS BIO, LLC (US) 2020-02-11 US disclosed
WO-2016077232-A2 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC (US) 2016-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11358961-B2 Anti-HCMV compositions and methods RPL35, RPL7, RPL5 LMNA 1720/4885RAB9A 3866/4885NOTUM 3271/4885
US-10556894-B2 Anti-HCMV compositions and methods RPL35, RPL7, RPL5 LMNA 1720/4885RAB9A 3866/4885NOTUM 3271/4885
US-20200140429-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 LMNA 1720/4885RAB9A 3866/4885NOTUM 3271/4885
US-20220135556-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 LMNA 1720/4885RAB9A 3866/4885NOTUM 3271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.